ringed sideroblasts is generally many fewer than 15%. The white cell and megakaryocyte series are not affected. Occasionally, patients develop severe sideroblastic anaemia secondary to drug therapy or severe alcohol abuse which may reverse on stopping the offending drug.7-' In the case of isoniazid, the mechanism is thought to be inhibition of pyridoxine related haemsynthesis; isoniazid binds pyridoxine and the complex is excreted via the kidney. 9 Penicillamine may have a similar mode of action.'0 A number of haematological side effects of penicillamine therapy have been reported.
Sullivan et all' reported a case of sideroblastic anaemia in a patient with biliary cirrhosis who was taking 1000 mg of penicillamine a day. The features of sideroblastic anaemia developed over 12 months and resolved after cessation of penicillamine and introduction of pyridoxine treatment. The patient later recommenced taking penicillamine with pyridoxine cover, without further problems. This patient had abnormal liver function and this may have contributed to the situation.
Ramselaar et al8 reported a patient who developed aplastic anaemia secondary to penicillamine. The leucopenia resolved, but the patient remained anaemic and thrombocytopenic with bone marrow features of sideroblastic anaemia. The patient did not respond to pyridoxine therapy and subsequently died of a septicaemic episode.
In our patient, the development of sideroblastic anaemia was closely associated with the introduction of penicillamine therapy and his rheumatoid arthritis was relatively quiescent as judged by clinical and laboratory parameters. On introduction of pyridoxine, the patient's anaemia resolved and the abnormal sideroblasts disappeared from the bone marrow. Thus the sudden onset of anaemia and the response to withdrawal of penicillamine strongly implicate penicillamine as the causal agent. The follow up bone marrow analysis showed only minor dysplastic features-a frequent finding in pyridoxine sensitive sideroblastic anaemia.
We believe that this is the first reported case of acquired sideroblastic anaemia which was reversible with pyridoxine, in a patient with rheumatoid arthritis. Might patients with HLA-B27 related diseases benefit from antiandrogenic treatmllent?
There are several rheumatic diseases which may be suspected of sharing the curious feature that both probands and their unaffected sibs have sex ratio biases that are in the same direction. For instance, rheumatoid arthritis (RA), early onset pauciarticular juvenile rheumatoid arthritis, and coxarthrosis are all conditions in which probands and their unaffected sibs seem to contain excesses of females, while ankylosing spondylitis (AS), Reiter's syndrome, and late onset pauciarticular juvenile rheumatoid arthritis are all conditions in which probands and their unaffected sibs seem to contain excesses of males.' 2 The caution in the foregoing sentence is appropriate, because many of the data underlying these conclusions were gathered for other purposes and were therefore subject to possible volunteer bias or survivorship bias (both of which would be expected to lead to female excesses). However, these qualifications do not apply to the data on juvenile rheumatoid arthritis;2 and they do not apply to recent reports of data explicitly gathered to test the sex ratio biases of sibs of RA and AS probands. 6 Tables 1  and 2 summarise these data; they suggest that the biases are real.
What may be inferred from this? One may propose that the same agent causes both the disease in probands and the unusual sex ratios in their unaffected sibs.
There is very substantial evidence that parental hormone levels at the time of conception partially control the sexes of human offspring at birth.7 8 So I suggested that low testosterone levels are a cause of RA and of RA patients' excess of sisters, and that high testosterone levels are a cause of AS and of these probands' excess of brothers.' The suspicion in regard to RA was strengthened by the subsequent demonstration that RA patients may benefit from androgen treatment.9 So the question arises if patients with HLA-B27 related diseases might, analogously, benefit from antiandrogen treatment. This resolves into the question: what evidence is there that HLA-B27 related diseases are partially caused by high levels of androgens?
For illustrative purposes, I shall consider AS (because there are more published data on this condition), but the following speculations may also apply to the other B27 related diseases. It is well established that patients with AS have high testosterone levels, on average. 1"12 Moreover, there is evidence that B27 is associated with high testosterone levels in healthy controls also.' 13 Thus the high testosterone levels in AS patients may reasonably be interpreted as a genetically determined precursor of the disease, rather than its consequence. This conclusion is strengthened by the observation that disease, in general, causes men's testosterone levels to decrease, not increase. '4 
